Dr. Gisa Gerstenberg

Position: Member of the Health Care Council. GLG Is an independent primary, global research firm serving business and investment leaders. It connects the decision-makers who are shaping and funding industries with industry experts. I act as an Expert in the Healthcare Council. Gerson Lehrman Group (GLG), founded in 1998 and headquartered in New York City, operates an expert network platform who provide independent consulting services to companies around the world.

Leadership responsibility for Medical Advisors, Medical Scientific Liaisons and Admin staff Budget Responsibility

Medical Responsibility for Oncology, including products like: Cabazitaxel (Jevtana®), Mozobil, Campath/MabCampath, Taxotere Leadership responsibility for the cross-functional medical oncology teams Providing Medical Affairs Leadership Leading integrated Brand Panning across all Therapeutic Areas

Independent Medical Advisor for pharmaceutical companies, professional service firms, private equity firms etc.

Responsible for Neuroscience pipeline and inlicensing assessments; strategic planning of drug development (life cycle, LE with new formulation or indication); protocol / study design; consultations with regulatory body; bridging; clinical development PhII up to Post Marketing Surveillance and marketing studies; publications; IITs; Joint work with S&M; opinion-leader networking.

•Responsible Physician for launch of the antipsychotic Olanzapine in Japan, achieving “Rocket start”; No. 1 share of market in 6 Months •Post marketing strategy incl. med. responsibility for clin. studies, publication strategy, IITs, opinion-leader networking, LE with new formulation/indication, bridging, PMDA consultation •Joint work with Sales & marketing providing med. input into marketing strategy / material / activities / MR training; carried out lectures on various Medical meetings in Japan

RESEARCH: Genetic polymorphism’s of drug metabolizing capacity (e.g. CYP450 subfamilies) Sensitivity at the site of action: serotonin transporter (5-HTT) and serotonin receptor (5-HT2A) Pharmacogenetic / interethnic difference, Genetic background of personality , Department of Neuro-Psychiatry LECTURE RESPONSIBILITIES: Psychiatry, medical English and patient interview techniques for medical students responsible for graduated Medical Doctors Pharmacogenetic Ph.D. research

GI and Oncologic Surgery with Prof. S. Satomi, Head of the Second Department of Surgery at Tohoku University School of Medicine, Sendai, Japan

1996-2001 Ph.D. research at the Institute of Psychosomatic Medicine; 1997 Assistant research fellow in the C.& O. Vogt-Institute for Brain-research